Whales with a lot of money to spend have taken a noticeably bearish stance on Vertex Pharmaceuticals.
Looking at options history for Vertex Pharmaceuticals (NASDAQ:VRTX) we detected 15 trades.
If we consider the specifics of each trade, it is accurate to state that 26% of the investors opened trades with bullish expectations and 46% with bearish.
From the overall spotted trades, 6 are puts, for a total amount of $334,455 and 9, calls, for a total amount of $522,634.
What’s The Price Target?
After evaluating the trading volumes and Open Interest, it’s evident that the major market movers are focusing on a price band between $350.0 and $500.0 for Vertex Pharmaceuticals, spanning the last three months.
Volume & Open Interest Trends
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Vertex Pharmaceuticals’s options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Vertex Pharmaceuticals’s substantial trades, within a strike price spectrum from $350.0 to $500.0 over the preceding 30 days.
Vertex Pharmaceuticals 30-Day Option Volume & Interest Snapshot
Significant Options Trades Detected:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| VRTX | CALL | SWEEP | BULLISH | 06/21/24 | $80.9 | $75.0 | $79.0 | $360.00 | $134.3K | 212 | 20 |
| VRTX | CALL | TRADE | BEARISH | 06/14/24 | $68.5 | $61.9 | $64.5 | $375.00 | $129.0K | 0 | 20 |
| VRTX | PUT | SWEEP | BEARISH | 06/21/24 | $6.3 | $5.9 | $6.2 | $430.00 | $114.5K | 103 | 199 |
| VRTX | PUT | SWEEP | BEARISH | 06/21/24 | $6.5 | $6.4 | $6.4 | $430.00 | $96.6K | 103 | 385 |
| VRTX | CALL | SWEEP | BULLISH | 06/21/24 | $10.0 | $9.7 | $10.0 | $440.00 | $48.0K | 434 | 77 |
About Vertex Pharmaceuticals
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid…
Click Here to Read the Full Original Article at Cryptocurrencies Feed…
